x
 
 
 
 

About Us

BOARD OF DIRECTORS

photo team

Dov Goldstein, M.D.

Independent Member

Dr. Goldstein brings more than two decades of experience in the biotech industry to the Gain board of directors. He is currently the Chief Financial and Business Officer of Indapta Therapeutics, a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple cancers. Prior to Indapta, Dr. Goldstein served as Chief Executive Officer at RIGImmune. From 2006-2019, he worked at Aisling Capital, a private investment firm. Dr. Goldstein also served as the Chief Financial Officer of Loxo Oncology, Inc. and Vicuron Pharmaceuticals, Inc., which was acquired by Pfizer, Inc. in September 2005. Dr. Goldstein has served as a director at ADMA Biologics, Inc., Esperion Therapeutics, Inc., and Cempra, Inc. (which was acquired by Melinta Therapeutics, Inc.). Dr. Goldstein received a B.S. from Stanford University, an M.B.A. from Columbia Business School, and an M.D. from Yale School of Medicine. He completed an internship in the Department of Medicine at Columbia-Presbyterian Hospital.

 

 
 
 

Research and Development Collaborations

lilly 

 

Grants

Grants Grants Grants Grants

 

Patient Associations

Patient Associations Patient Associations Patient Associations Patient Associations

Centers of Research, Translational Science & Clinical Excellence

Centers of Research Centers of Research Centers of Research Centers of Research Centers of Research Centers of Research
Centers of Research Centers of Research Centers of Research Centers of Research Centers of Research Centers of Research
 

Interested in working with a dynamic team of research,
medical and business professionals? 

View Job opportunities